Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $62.92 USD
Change Today -0.02 / -0.03%
Volume 868.6K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 1:52 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Snapshot

Open
$61.33
Previous Close
$62.94
Day High
$63.73
Day Low
$61.33
52 Week High
03/5/15 - $75.17
52 Week Low
10/13/14 - $38.49
Market Cap
9.3B
Average Volume 10 Days
1.5M
EPS TTM
$-0.60
Shares Outstanding
148.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (ALKS)

alkermes plc (ALKS) Related Businessweek News

View More BusinessWeek News

alkermes plc (ALKS) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

1,300 Employees
Last Reported Date: 02/24/15
Founded in 1987

alkermes plc (ALKS) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $810.2K
President
Total Annual Compensation: $579.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $444.1K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $435.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $435.5K
Compensation as of Fiscal Year 2013.

alkermes plc (ALKS) Key Developments

Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research

Alkermes plc announced that clinical data on aripiprazole lauroxil, an investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia, and ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia, are scheduled to be presented at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, Colo., March 28-April 1, 2015. Aripiprazole lauroxil is an injectable atypical antipsychotic with one-month and extended-duration formulations in development for the treatment of schizophrenia. Once in the body, aripiprazole lauroxil converts to aripiprazole, which is commercially available under the name ABILIFY. As a long-acting investigational medication based on Alkermes proprietary LinkeRx technology, aripiprazole lauroxil is designed to have multiple dosing options and to be administered in a ready-to-use, pre-filled product format. ALKS 3831 is a proprietary, investigational medicine designed as a broad-spectrum antipsychotic for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, potent mu-opioid antagonist, in combination with the established antipsychotic drug, olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, in patients with schizophrenia and to have utility in the treatment of schizophrenia in patients with alcohol use.

Alkermes plc Revises Earnings Guidance for the Fiscal Year of 2015

Alkermes plc revised Earnings Guidance for the fiscal year of 2015. For the period, the company expects non-GAAP net loss to widen to a range of $0.37 to $0.50 per share from the previous guidance of $0.27 to $0.40. The transaction could also decrease revenues by approximately $40 million to a range of $600 million to $630 million, revised from the original target of $640 million to $670 million. The company continues to expect net interest expense to range from $10 million to $15 million. GAAP net loss will increase by approximately $15 million, to be in the range of $270 million to $300 million, and a basic and diluted loss per share of $1.80 to $2.00, This is revised from an expectation of a GAAP net loss of $255 million to $285 million, and a basic and diluted loss per share of $1.70 to $1.90. The company expects that non-GAAP net loss will increase by approximately $15 million, to be in the range of $55 million to $75 million, this is revised from an expectation of a basic and diluted non-GAAP net loss per share of $0.27 to $0.40. The company expects that capital expenditures will decrease by approximately $5 million, to be approximately $50 million, revised from an expectation of approximately $55 million. The company expects that free cash outflow will increase by approximately $10 million, to be in the range of $105 million to $125 million. This is revised from an expectation of a free cash outflow of $95 million to $115 million.

Geraldine Henwood Resigns as Member of Board of Alkermes Public Limited Company

On March 7, 2015, Geraldine Henwood notified the Board of Alkermes Public Limited Company that she would be resigning as a member of the company’s Board effective immediately. Ms. Henwood’s decision was not the result of any disagreement between the company and Ms. Henwood on any matter, including with respect to the company’s operations, policies or practices.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $62.91 USD -0.035

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.164.80 CHF -2.20
Jazz Pharmaceuticals PLC $176.68 USD +3.29
Pacira Pharmaceuticals Inc/DE $92.45 USD +1.34
Ranbaxy Laboratories Ltd 805.20 INR -14.10
Salix Pharmaceuticals Ltd $172.69 USD +0.06
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 6.6x
Price/Cash Flow 329.2x
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.